Experts are studying a variety of newer treatments for severe alopecia areata, and early results look promising. Clinical trials. Talk to your doctor about joining a clinical trial. If it’s ...

Everyone’s alopecia areata is different. Even though everyone who has it experiences hair loss, it may have many variations, including where, when, and how often you lose your hair. Alopecia ...

A NEW mum who wanted a new bust after having her baby has lost all of her hair following the operation – including her eyelashes and eyebrows. The silicone implants Czech dental worker ...

BMO Capital Markets adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotechnology firm's stock rating from Outperform to Market Perform, accompanied by a significant decrease in ...

According to a recent study, comorbid chronic inflammatory diseases influence the prognosis of alopecia areata.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

BMO Capital downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $3, down from $22. The company announced an ...

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...